Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and operational highlights announced for quarter ended June 30, 2026.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and operational highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial and operational information
- Filing under Item 2.02 signals earnings disclosure for investor review
Item 8.01 · Other Events
- Updated investor presentation posted August 4, 2026, signaling refreshed corporate and pipeline messaging
- Exhibit 99.2 contains the substantive presentation for investors and analysts
- Ongoing use in meetings may influence market expectations around Larimar’s development programs
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $32.8M, or $0.30/share, versus $26.2M, reflecting accelerating development and commercialization spending
- Cash, equivalents and marketable securities $156.3M at June 30, supporting runway into Q3 2027 without near-term financing indicated
- Rolling BLA underway after FDA alignment, with completion targeted for 2H 2026 and accelerated approval dependent on regulatory review
- Phase 3 confirmatory dosing expected Q3 2026, a key validation milestone for nomlabofusp’s potential approval pathway
- Safety and efficacy signals remain supportive, though 10 anaphylaxis cases caused study discontinuations among 43 participants
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.